Avastin News and Research

RSS

Avastin is a biologic antibody designed to specifically bind to a protein called vascular endothelial growth factor (VEGF) that plays an important role throughout the lifecycle of the tumor to develop and maintain blood vessels, a process known as angiogenesis. Avastin is designed to interfere with the blood supply to a tumor by directly binding to the VEGF protein to prevent interactions with receptors on blood vessel cells. Avastin does not bind to receptors on normal or cancer cells. The tumor blood supply is thought to be critical to a tumor’s ability to grow and spread in the body (metastasize).

Mays Cancer Center conducts clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma

The Mays Cancer Center at The University of Texas Health Science Center at San Antonio recently conducted a clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma (GBM).

24 May 2023

Researchers receive $3.3 million NIH grant to study spectroscopic MRI for glioblastoma detection

Collaborative project with Emory University will refine groundbreaking spectroscopic MRI technology to make it easier to use.

25 Jan 2023

Private equity sees the billions in eye care as firms target high-profit procedures

Christina Green hoped cataract surgery would clear up her cloudy vision, which had worsened after she took a drug to fight her breast cancer.

19 Sep 2022

A stepped regimen of anti-VEFG drugs leads to good vision outcomes in diabetic macular edema

Clinical trial results from the DRCR Retina Network suggest that a specific step strategy, in which patients with diabetic macular edema start with a less expensive medicine and switch to a more expensive medicine if vision does not improve sufficiently, gives results similar to starting off with the higher-priced drug.

14 Jul 2022

Treatment for retinal vein occlusion yields long-lasting vision gains, study shows

New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years.

21 Apr 2022

bit.bio expands Board of Directors with appointment of entrepreneurs and Nobel Laureate

Today bit.bio welcomed three new members to its Board of Directors, who bring their respective experience of turning world-class science into new industries.

From bit.bio 27 Oct 2021

Why we may never know whether the $56,000-a-year Alzheimer’s drug actually works

The Food and Drug Administration's approval in June of a drug purporting to slow the progression of Alzheimer's disease was widely celebrated, but it also touched off alarms.

12 Jul 2021

Researchers develop first report card on biosimilars for three blockbuster cancer drugs

Researchers have developed the first report card on biosimilars for three blockbuster cancer drugs marketed by Genentech/Roche: Rituxan, Avastin, and Herceptin.

2 Dec 2020

New combination treatment for recurrent ovarian cancer shows positive outcomes

A team from Roswell Park Comprehensive Cancer Center has detailed striking findings on the effectiveness of a previously untried combination of old and new drugs as treatment for recurrent ovarian cancer.

19 Nov 2020

Two studies find age as a primary factor in melanoma treatment resistance

Age may cause identical cancer cells with the same mutations to behave differently. In animal and laboratory models of melanoma cells, age was a primary factor in treatment response.

2 Nov 2020

Age can affect response to adjuvant treatment among patients with resected melanoma

Younger patients with resected melanoma had some benefit from adjuvant treatment with the anti-VEGF therapeutic bevacizumab (Avastin) while older patients with resected melanoma did not

23 Oct 2020

Common medication used to treat diabetic macular edema is less effective in Black patients

A medication frequently used to treat diabetic macular edema, which is the most common cause of blindness in people with diabetes, is less effective when used to treat the condition in Black patients, new study results show.

22 Oct 2020

New treatment improves survival for people with common liver cancer

For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.

13 May 2020

A faster and easier treatment option to prevent blindness in preterm infants

Babies born prematurely who require treatment to prevent blindness from retinopathy of prematurity (ROP) could be treated with a dose of Avastin (bevacizumab) that is a fraction of the dose commonly used for ROP currently.

23 Apr 2020

UCI makes tremendous strides in prevention, early detection and treatment of cancer

Like most people, John Gifford wasn't looking forward to a colonoscopy when he arrived on the UCI Medical Center campus in Orange in 2018.

23 Feb 2020

New combination of antibodies leads to more effective tumor destruction

The simultaneous use of antibodies based on two differing mechanisms of action leads to a more effective destruction of tumors.

30 Dec 2019

RTKI drugs may not significantly improve survival rates of patients during radiotherapy

Taking certain cancer-fighting drugs while undergoing radiation therapy may not increase survival for patients, but may, instead, increase side effects, according to a team of researchers. The drugs, however, may be beneficial for patients who are not undergoing radiation therapy.

10 Oct 2019

Avastin News and Research

Further Reading